Developing Next-Generation Treatments for Herpes Simplex-Induced diseases

Read More
image

About us

With its clinical and medical experts, the team of Innovative Molecules dedicates its work to patients suffering from herpes mediated diseases.

Pipeline

IM-250 is a novel, orally available, selective HSV-helicase primase inhibitor. Helicase primase inhibitors block unwinding of DNA in the ...

News

Latest News, Media,
Press Releases and Updates

News / Press

Our Latest News & Press

Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV
27 October 2023

Intermittent therapy with helicase-primase inhibitor IM-250 efficiently controls recurrent herpes disease and reduces reactivation of latent HSV

Read More +
Innovative Molecules Announces First Subjects Dosed in the German Phase 1 Clinical Trial of IM-250
15 June 2023

Innovative Molecules Announces First Subjects Dosed in the German Phase 1 Clinical Trial of IM-250

Read More +
Science Translational Medicine Publication: Innovative Molecules ́ Drug Candidate Affects Recurrent Herpes Simplex Virus Infections
16 June 2021

Science Translational Medicine Publication: Innovative Molecules ́ Drug Candidate Affects Recurrent Herpes Simplex Virus Infections

Read More +
Innovative Molecules raises €20 million Series A equity financing round
07 June 2021

Innovative Molecules raises €20 million Series A equity financing round

Read More +

With its clinical and medical experts, the team of Innovative Molecules dedicates its work to patients suffering from herpes mediated-diseases.

Quick Links

Information

  • Email

Copyright © 2016 - 2023 Innovative Molecules. Developed by Workshop Agency